This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ni, Z. Articles by Vaziri, N. D. Search for Related Content PubMed PubMed Citation Articles by Ni, Z. Articles by Vaziri, N. D.

(Hypertension. 1998;32:724-729.)
© 1998 American Heart Association, Inc.

Scientific Contributions

Nitric Oxide Metabolism in Erythropoietin-Induced Hypertension

Effect of Calcium Channel Blockade

Zhenmin Ni; Xiu Q. Wang; ; Nosratola D. Vaziri

From the Department of Medicine, Division of Nephrology, University of California at Irvine.

Abstract—Long-term administration of erythropoietin (EPO) frequently causes hypertension in humans and animals with chronic renal failure (CRF). We recently demonstrated that EPO-induced hypertension is hematocrit independent and accompanied by elevated cytosolic [Ca²⁺]_i and nitric oxide (NO) resistance. This study was undertaken to examine the effects of therapy with EPO alone or together with calcium channel blockade on NO metabolism. Urinary excretion of NO metabolites (NOx) and thoracic aorta and kidney endothelial and inducible NO synthases (eNOS and iNOS) were studied in 4 groups of 6 nephrectomized rats treated with either placebo, EPO, the calcium channel blocker felodipine, or EPO plus felodipine for 6 weeks. A group of sham-operated placebo-treated animals served as control. The placebo-treated CRF group exhibited moderate hypertension, elevated basal and depressed stimulated platelet [Ca²⁺]_i, reduced urinary NOx excretion, and diminished vascular and renal eNOS and iNOS proteins. EPO therapy further raised blood pressure and increased resting and stimulated [Ca²⁺]_i but did not change NOx excretion or NOS proteins. Concurrent administration of felodipine abrogated EPO-induced hypertension, normalized resting and stimulated [Ca²⁺]_i, and increased NOx excretion and eNOS and iNOS proteins. Thus, EPO therapy leads to marked increases in blood pressure and resting and stimulated [Ca²⁺]_i. These abnormalities are ameliorated by calcium channel blockade, which restores [Ca²⁺]_i to normal and increases vascular and renal NOS expression.

Key Words: nitric oxide synthase • renal disease • calcium • erythropoietin • calcium channel blockers • hypertension

This article has been cited by other articles:

				E. Podjarny, G. Hasdan, J. Bernheim, G. Rashid, J. Green, Z. Korzets, and J. Bernheim Effect of chronic tetrahydrobiopterin supplementation on blood pressure and proteinuria in 5/6 nephrectomized rats Nephrol. Dial. Transplant., September 1, 2004; 19(9): 2223 - 2227. [Abstract] [Full Text] [PDF]

				X. Chu, Q. Tong, J. Y. Cheung, J. Wozney, K. Conrad, V. Mazack, W. Zhang, R. Stahl, D. L. Barber, and B. A. Miller Interaction of TRPC2 and TRPC6 in Erythropoietin Modulation of Calcium Influx J. Biol. Chem., March 12, 2004; 279(11): 10514 - 10522. [Abstract] [Full Text] [PDF]

				N. D. Vaziri, Y. Ding, and Z. Ni Compensatory Up-Regulation of Nitric-Oxide Synthase Isoforms in Lead-Induced Hypertension; Reversal by a Superoxide Dismutase-Mimetic Drug J. Pharmacol. Exp. Ther., August 1, 2001; 298(2): 679 - 685. [Abstract] [Full Text] [PDF]

				R. Govers and T. J. Rabelink Cellular regulation of endothelial nitric oxide synthase Am J Physiol Renal Physiol, February 1, 2001; 280(2): F193 - F206. [Abstract] [Full Text] [PDF]

				N. D. Vaziri, X. Q. Wang, F. Oveisi, and B. Rad Induction of Oxidative Stress by Glutathione Depletion Causes Severe Hypertension in Normal Rats Hypertension, July 1, 2000; 36(1): 142 - 146. [Abstract] [Full Text] [PDF]

				D. S. Sangha, N. D. Vaziri, Y. Ding, and R. E. Purdy Vascular hyporesponsiveness in simulated microgravity: role of nitric oxide-dependent mechanisms J Appl Physiol, February 1, 2000; 88(2): 507 - 517. [Abstract] [Full Text] [PDF]

				Y. Ding and N. D. Vaziri Nifedipine and Diltiazem but Not Verapamil Up-Regulate Endothelial Nitric-Oxide Synthase Expression J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 606 - 609. [Abstract] [Full Text]

				Z. Ni, F. Oveisi, and N. D. Vaziri Nitric Oxide Synthase Isotype Expression in Salt-Sensitive and Salt-Resistant Dahl Rats Hypertension, October 1, 1999; 34(4): 552 - 557. [Abstract] [Full Text] [PDF]

				E. BROCHU, S. LACASSE-M, R. LARIVIÈRE, I. KINGMA, J. H. GROSE, and M. LEBEL Differential Effects of Endothelin-1 Antagonists on Erythropoietin-Induced Hypertension in Renal Failure J. Am. Soc. Nephrol., July 1, 1999; 10(7): 1440 - 1446. [Abstract] [Full Text]

				X. Q. Wang and N. D. Vaziri Erythropoietin Depresses Nitric Oxide Synthase Expression by Human Endothelial Cells Hypertension, March 1, 1999; 33(3): 894 - 899. [Abstract] [Full Text] [PDF]